All News

The FDA granted breakthrough therapy designation to an autologous CAR-T cell therapy for pediatric patients with diffuse intrinsic pontine glioma.

An expert sat down to discuss the emotional and physical barriers patients may face when seeking support for fear of cancer progression.

People can help EBCI reach their goal of $20,000 dollars raised for GiveBIG 2025 by giving at endbraincancer.org/donate.

It’s spring, a time for new beginnings following a cancer diagnosis; however, I have an ongoing issue that I can’t dismiss.

The Oncodetect test detects molecular residual disease across solid tumors using circulating tumor DNA to inform recurrence risk and treatment decisions.

Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder cancer, based on the NIAGARA trial.

“Don’t aspire to make a living. Let’s aspire to make a difference in the Mandarin/Cantonese-speaking community.”

Carly Stafford Dixon, a rare cancer survivor, highlights the need for AYA cancer awareness to improve support, visibility and access to vital resources.

Clinical trials improve care and access to novel treatments for advanced gastrointestinal cancers, says Dr. Michael Pishvaian.

Diagnosed in 2014, I share my unique aggressive treatment journey over 11 years, highlighting a common hope for more time and better treatments.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.

In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in disease progression.

Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be recommended, a trial found.

After nearly 30 years with cancer — community, research and education have helped us find hope, strength and purpose in the face of chronic blood cancers.

Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the JAVELIN Bladder 100 trial.

Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial.

The journey that led to the creation of the Extraordinary Healer Award for Oncology Nursing began with a simple, yet profound, observation.

Dr. Rugo has led key breast cancer therapy trials and exudes a passion for serving patients.

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were treated in the advanced setting.

Dr. Zafar Sayed discuss the importance of recognizing Head and Neck Cancer Awareness Month and highlights early symptoms of the disease to be aware of.

An AI model may help identify patients with myelofibrosis at high risk of early death after transplant, according to an expert.

Each spring, I find strength and hope in the daffodils I grow, helping me face chronic lymphocytic leukemia with renewed determination.

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus immune checkpoint inhibitors.